CMS Open Payments · Program Year 2024
Tempus AI, Inc
Tempus AI, Inc reported $683,535.58 across General Payments, Research, and Ownership to 14,627 physicians and teaching hospitals across 14,627 transactions.
- $683.5K Above-median payer
- All-tracks total
- 14,627 Top 10% volume
- Transactions
- 14,627 Top 10% reach
- Recipients
- #697
- of 1,925 companies
Tempus AI, Inc reported $683,535.58 across all CMS Open Payments tracks (General + Research + Ownership) to 14,627 physicians and teaching hospitals in Program Year 2024 - ranking #697 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $683,535.58, averaging $46.73 per recipient.
Tempus AI, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
63/100
Total payments
F
16/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer tempus-ai-inc Tempus AI, Inc
$683.5K · #697/1,925 · 0.0% industry · PY2024
- TOT $683.5K
- RANK #697
- SHARE 0.0%
- TXN 14,627
- RCP 14,627
- CAT 3
- GEN $683.5K
- TOP1 6.1%
- PY 2024
Volume peers
Nearest volume peer: SNAP Diagnostics LLC ($687.2K)
Tempus AI, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Tempus AI, Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Tempus AI, Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
14,469 transactions worth $430.9K make "Food and Beverage" the top general-payment category in the 3-category breakdown below, 63.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Tempus AI, Inc's 3-category general-payment breakdown at $430.9K, 63.0% of the reported total.
How Tempus AI, Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $430.9K | 14,469 | 63.0% |
| Consulting Fee | $239.8K | 113 | 35.1% |
| Travel and Lodging | $12.9K | 45 | 1.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $121,651.91 (17.8%) of $683,535.58 in this company's General Payments records across 7,999 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Tempus AI, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Mahran Shoukier
$41,943.88 across 14 reported transactions
- 2
Amol Rao
$35,126.37 across 5 reported transactions
- 3
Bobby Chawla
$20,886.86 across 33 reported transactions
- 4
Anthony Mato
$11,975.00 across 8 reported transactions
- 5
Vijay Gunuganti
$11,719.80 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Tempus AI, Inc ranks #697 of 1,925 by total payments (top 36% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,700 of 1,838 by HHI (bottom 8% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Arcutis Biotherapeutics, Inc. : $5.0M total payments, HHI 97
- CVRx, Inc. : $1.5M total payments, HHI 97
- Peerless Surgical Inc. : $139.0K total payments, HHI 96
- Gemini Mountain Medical, LLC : $85.4K total payments, HHI 96
- InSightec,Inc : $120.8K total payments, HHI 96
- Mid-Atlantic Surgical Systems, LLC : $92.4K total payments, HHI 95
- Tempus AI, Inc (this company) : $683.5K total payments, HHI 95
- Validus Pharmaceuticals LLC : $12.3K total payments, HHI 95
- CSL Behring : $4.9M total payments, HHI 91
- Biotissue Holdings Inc. : $2.1M total payments, HHI 90
- Kerecis Limited : $4.0M total payments, HHI 89
- Elite Orthopedics, Llc : $97.1K total payments, HHI 89
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Tempus AI, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Tempus AI, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Tempus AI, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Kaneka Medical America LLC
Synapse Surgical LLC
Extremity Medical
Verathon Inc.
Teleflex Incorporated
Put this to use
Tempus AI, Inc ranks #697 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Tempus AI, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.